ARLINGTON, Virginia,
NEW YORK and CAESAREA, Israel, May
3, 2019 /PRNewswire/ -- Global digital therapeutics
innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced that
it is partnering with the American Diabetes Association as a Living
Red Sponsor of NYC - Step Out®: Walk to Stop
Diabetes®.
This partnership advances the ADA's mission to prevent and cure
diabetes while improving the lives of all people with the
disease.
Dario will publish several studies performed using de-identified
data from its broad data base of users, demonstrating the clinical
benefits of its Digital Therapeutics (DTx) solution to help improve
life with diabetes and achieve clinically-proven results at the
ADA's 2019 Scientific Sessions conference in June 2019.
Dario offers a user mobile application to engage and educate its
users on topics ranging from diabetes management to healthy
nutrition and exercise as well as a platform that allows healthcare
professionals to access collected data and to provide
recommendations to the individuals they are supporting. Data is
collected from devices such as the acclaimed Dario 3-in-1 blood
glucose meter and other applications. Dario is an open system
accepting connections with third party devices and external health
coaches. It delivers aggregated analytics demonstrating the
efficacy of its interventions.
Dario's digital platform has delivered tangible results to tens
of thousands of users in the U.S. and abroad, and it has received
outstanding reviews on the Apple store (4.9 / 5.0 with close to
5,000 reviews) and Google Play (4.3 / 5.0 with more than 2,000
reviews).
"We are honored and humbled to be recognized by the ADA as an
organization that can advance the ADA's cause of preventing and
curing diabetes," commented Erez
Raphael, DarioHealth's CEO. "Dario is striving to use its
technology and expertise to engage its users in adopting healthier
habits, with scientific-based results."
"There are more than 30 million Americans living with diabetes,
including over 2 million here in the state of New York," added Lauren Grosz, Executive Director of the ADA in
New York City. "We appreciate
Dario's demonstrated commitment to supporting the ADA mission and
helping us bend the curve on diabetes."
About the American Diabetes Association
Approximately every 21 seconds, someone in the United States is diagnosed with diabetes.
Nearly half of the American adult population has diabetes or
prediabetes, and more than 30 million adults and children are
living with the disease. The American Diabetes Association (ADA) is
the nation's leading voluntary health organization on a mission to
prevent and cure diabetes, as well as improve the lives of all
people affected by the disease. For nearly 80 years, the ADA has
driven discovery by funding research to treat, manage and prevent
all types of diabetes, while working relentlessly for a cure.
Magnifying the urgency of this epidemic, the ADA works to safeguard
policies and programs that protect people with the illness, those
at risk of developing diabetes and the health care professionals
who serve them by initiating programs, advocacy and education
efforts that can lead to improved health outcomes and quality of
life. To learn more or to get involved, call 1-800-DIABETES
(1-800-342-2383) or visit diabetes.org. Information is available in
English and Spanish. Join the conversation with the ADA on Facebook
(American Diabetes Association), Twitter (@AmDiabetesAssn) and
Instagram (@AmDiabetesAssn).
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital
therapeutics company revolutionizing the way people manage their
health across the chronic condition spectrum. By delivering
evidence-based interventions that are driven by accumulated data,
high-quality software and coaching, we developed a novel approach
that empowers individuals to adjust their lifestyle in a
personalized way. Our Cross Functional Team operates at the
intersection of life sciences, behavioral science and software
technology to deliver highly engaging therapeutic interventions.
Already one of the highest rated diabetes solutions, its
user-centric approach is loved by tens of thousands of consumers
around the globe. DarioHealth is rapidly moving into new chronic
conditions and geographic markets.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company states
that it will publish several studies performed using de-identified
data from its broad data base of users to help improve life with
diabetes and achieve clinically-proven results, it is using
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Contact:
Joao Mendes-Roter
VP Marketing
joao@mydario.com
+1-347-767-4220
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-announces-new-partnership-with-the-american-diabetes-association-300843447.html
SOURCE DarioHealth Corp.